The Effects Of Glibenclamide On Cognitive Performance, Quality Of Life, And Emotional Aspects Among Patients With Aneurysmal Subarachnoid Hemorrhage: A Randomized Controlled Trial

Isabela Costola Windlin,Bruno Braga Sisnando da Costa,João Paulo Mota Telles,Leonardo B. Oliveira,Edwin Koterba,Vitor Nagai Yamaki,Nicollas Nunes Rabelo,Davi Jorge Fontoura Solla,Manoel Jacobsen Teixeira,Eberval Gadelha Figueiredo
DOI: https://doi.org/10.1016/j.wneu.2024.09.048
IF: 2.21
2024-09-15
World Neurosurgery
Abstract:Introduction Aneurysmal subarachnoid hemorrhage (aSAH) is associated with a high incidence of long-term cognitive impairment, decreased quality of life (QoL), and psychiatric disorders. The effects of glibenclamide on such outcomes in the setting of aSAH is unknown. Objective To assess the impact of glibenclamide in patients with aSAH on cognitive performance, QoL, and emotional aspects. Methods Patients identified with aSAH were randomly allocated to receive 5mg of glibenclamide for 21 days or placebo, starting within 96 hours of the ictus. After six months, patients were evaluated with MoCA test (cognitive performance), SF-36 (QoL), and HADS and SPTSS (emotional aspects). Results The mean MoCA score was 22.5 ± 6.2. No statistically significant difference was found between groups, with a mean score of 21.7 ± 6.4 in the Glibeclamide group and 23.4 ± 6.2 in the placebo group (p=0.392). A score 0.05). In each domain, the mean score was similar between groups (p>0.05). The HADS scores did not differ between groups (p>0.05). The mean SPTSS score as well as the mean scores of its domains were similar between groups (p>0.05). Conclusions Glibenclamide did not improve cognitive performance, QoL, and emotional aspects after six months of follow-up of aSAH survivors.
surgery,clinical neurology
What problem does this paper attempt to address?